LUND, SWEDEN – Immunovia AB (publ) ) (“Immunovia”), a diagnostic company that develops highly accurate blood based tests for the early detection of cancer and autoimmune diseases, today announced that The Crown Princess of Sweden and Prince Daniel visited Medicon Village and two innovative companies of their choosing, Immunovia and Idogen. The delegation included the Governor of Skåne County, Anneli Hultén and additional representatives from Skåne County Administrative Board and the Royal Court.The visit began with Kerstin Jakobsson, CEO, Medicon Village who introduced to the distinguished guests to the successful concept of Medicon Village in which innovation is brought from academic research to the patients through the companies that make up Medicon Village.
The visit continued with a presentation of Immunovia by Laura Chirica, CCO, which focused on Immunovia’s breakthrough technology platform, IMMray™, and IMMray™ PanCan-d, the blood test designed for early detection of pancreatic cancer. The Crown Princess and Prince Daniel, together with the other members of the delegation, then toured Immunovia’s analysis lab, shown by Linda Mellby, VP R&D and Madeleine Rosén, Laboratory Director and was followed by a production demo given by Viktor Fransson, Production Technician in Immunovia’s test production facility. The laboratory demonstrations were carried out in Immunovia’s IMMray™ Dx Laboratory Services facility in Lund, Sweden.
The visit ended with the Idogen introduction given by Anders Karlsson, CEO, followed by a scientific presentation given by Hanne Romedahl, CSO, about how Idogen develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissues.
Mats Grahn, CEO of Immunovia commented, “We were thrilled to receive such a distinguished visit to Immunovia in Lund. We are grateful to The Crown Princess of Sweden and Prince Daniel‘s for their interest in our company and in IMMray™ – state-of-the-art technology as part of their engagement to promote Swedish innovations.“ (Link to PR Medicon Village in Swedish)
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Tel: +46 7 93 486 277
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique “disease biomarker signature”.
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d ,is undergoing clinical evaluation in some of the world’s largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently entering the final validation for sales start Q3 2020. When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.